These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37739220)

  • 1. Two-year clinical outcomes of drug-coated balloon angioplasty and angiographic predictors of restenosis among patients with de novo femoropopliteal lesions.
    Yamaguchi K; Mori S; Fukagawa T; Kishida T; Nakano T; Shirai S; Mizusawa M; Makino K; Honda Y; Tsutsumi M; Kobayashi N; Yamawaki M; Ito Y
    Indian Heart J; 2023; 75(6):403-408. PubMed ID: 37739220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
    Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
    J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
    JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion.
    Soga Y; Takahara M; Iida O; Tomoi Y; Kawasaki D; Tanaka A; Yamauchi Y; Tobita K; Kozuki A; Fujihara M; Ando K;
    J Am Heart Assoc; 2023 Jan; 12(1):e025677. PubMed ID: 36583431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
    Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study).
    Shishehbor MH; Zeller T; Werner M; Brodmann M; Parise H; Holden A; Lichtenberg M; Parikh SA; Kashyap VS; Pietras C; Tirziu D; Ardakani S; Beschorner U; Krishnan P; Niazi KA; Wali AU; Lansky AJ
    Circulation; 2022 May; 145(22):1645-1654. PubMed ID: 35377157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of non-flow-limiting spiral dissection after drug-coated balloon angioplasty for de novo femoropopliteal lesions.
    Haraguchi T; Kuramitsu S; Tsujimoto M; Kashima Y; Sato K; Fujita T
    Catheter Cardiovasc Interv; 2024 Jan; 103(1):97-105. PubMed ID: 37975201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
    Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
    JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiographic patterns of restenosis after drug-coated balloon angioplasty for femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy.
    Higashino N; Iida O; Ishihara T; Hata Y; Toyoshima T; Tsukizawa T; Nishian K; Fujihara M; Kawasaki D; Mano T
    Catheter Cardiovasc Interv; 2023 Nov; 102(6):1114-1121. PubMed ID: 37855184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mid- and long-term outcomes and prognostic factors of drug-coated balloon angioplasty for treatment of femoropopliteal long lesions].
    Cao ZJ; Zhang T; Zhao KQ; Zhao JL; Yu XH; Li YW; Wu WW
    Zhonghua Wai Ke Za Zhi; 2022 Jan; 60(1):57-62. PubMed ID: 34954948
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes.
    Rodoplu O; Oztas DM; Meric M; Beyaz MO; Ulukan MO; Yildiz CE; Unal O; Ugurlucan M
    Ann Vasc Surg; 2021 May; 73():222-233. PubMed ID: 33359329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Ghanian S; Parikh SA; Secemsky EA; Schneider PA; Armstrong EJ
    J Endovasc Ther; 2020 Aug; 27(4):647-657. PubMed ID: 32508220
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequency, predictors, and effect of the slow-flow phenomenon after drug-coated balloon angioplasty for femoropopliteal lesions.
    Shirai S; Hirano K; Mori S; Makino K; Honda Y; Tsutsumi M; Sakamoto Y; Kobayashi N; Araki M; Yamawaki M; Ito Y
    Heart Vessels; 2021 Dec; 36(12):1818-1824. PubMed ID: 34050788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of the Size of Drug-Coated Balloon Therapy on Restenosis Rate in Femoropopliteal Lesions.
    Kurata N; Iida O; Takahara M; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Hata Y; Mano T
    J Endovasc Ther; 2023 Apr; 30(2):269-280. PubMed ID: 35249409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population.
    Chen Z; Guo W; Jiang W; Wang F; Fu W; Zou Y; Deckers S; Li P; Popma JJ; Jaff MR
    J Endovasc Ther; 2019 Aug; 26(4):471-478. PubMed ID: 31204595
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraluminal vs Subintimal Drug-Coated Balloon Angioplasty for the Treatment of Femoropopliteal Chronic Total Occlusions.
    Toyoshima T; Takahara M; Iida O; Tomoi Y; Kawasaki D; Tanaka A; Yamauchi Y; Tobita K; Kozuki A; Fujihara M; Higuchi Y; Soga Y;
    JACC Cardiovasc Interv; 2024 Mar; 17(5):608-618. PubMed ID: 38479962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.